Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced the issuance of 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc., marking the achievement of a significant milestone under their License Agreement dated August 16, 2023. This development is expected to enhance Imugene’s operational capabilities and strengthen its position in the biotechnology sector by advancing its collaborative efforts with Precision Biosciences.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development and commercialization of novel immunotherapies that activate the immune system of cancer patients to treat and eradicate tumors. The company’s primary products and services are centered around innovative cancer treatment solutions.
YTD Price Performance: -70.99%
Average Trading Volume: 2,758,458
Technical Sentiment Signal: Sell
Current Market Cap: A$108M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.